181 related articles for article (PubMed ID: 17200362)
1. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
Yee LD; Williams N; Wen P; Young DC; Lester J; Johnson MV; Farrar WB; Walker MJ; Povoski SP; Suster S; Eng C
Clin Cancer Res; 2007 Jan; 13(1):246-52. PubMed ID: 17200362
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
3. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
4. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo.
Kumar AP; Quake AL; Chang MK; Zhou T; Lim KS; Singh R; Hewitt RE; Salto-Tellez M; Pervaiz S; Clément MV
Cancer Res; 2009 Nov; 69(22):8636-44. PubMed ID: 19887620
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
7. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.
Emery MN; Leontiou C; Bonner SE; Merulli C; Nanzer AM; Musat M; Galloway M; Powell M; Nikookam K; Korbonits M; Grossman AB
Clin Endocrinol (Oxf); 2006 Sep; 65(3):389-95. PubMed ID: 16918962
[TBL] [Abstract][Full Text] [Related]
8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
Tencer L; Burgermeister E; Ebert MP; Liscovitch M
Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
[TBL] [Abstract][Full Text] [Related]
14. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
16. [Effects of different dietary fatty acid on expression of nuclear receptor genes in breast cancer of rats].
Wei N; Mi MT; Wang B; Zhu JD; Zhu DP; Yuan JL
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jul; 41(4):271-6. PubMed ID: 17959046
[TBL] [Abstract][Full Text] [Related]
17. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
19. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.
Yamamoto Y; Ono T; Dhar DK; Yamanoi A; Tachibana M; Tanaka T; Nagasue N
J Gastroenterol Hepatol; 2008 Jun; 23(6):930-7. PubMed ID: 18565023
[TBL] [Abstract][Full Text] [Related]
20. Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone.
Yee LD; Young DC; Rosol TJ; Vanbuskirk AM; Clinton SK
J Nutr; 2005 May; 135(5):983-8. PubMed ID: 15867269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
